Back to Peptide Index

Ipamorelin

MetabolicEvidence Level: researchNot FDA-approved for general therapeutic use; research use only
Peptide #06

Ipamorelin is a synthetic pentapeptide known for its potent and selective growth hormone (GH)-releasing properties. It mimics ghrelin, a hormone naturally produced in the body, effectively stimulating GH secretion with minimal side effects. Although not FDA-approved for general therapeutic use, extensive research underscores Ipamorelin’s promising applications in enhancing growth hormone levels, improving body composition, and supporting anti-aging therapies.

Overview

Ipamorelin is a peptide being explored for how it may naturally encourage the body to release more growth hormone. Ongoing research is focused on its potential roles in muscle development, fat metabolism, and healthy aging.

How It Works

Ipamorelin specifically binds to ghrelin receptors in the pituitary gland, triggering a natural, pulsatile release of growth hormone.

Clinical Effects

Enhances body composition, promotes lean muscle mass development, reduces body fat, supports healthier skin, improves sleep quality, increases energy levels, and optimizes metabolism.

Therapeutic Applications

Muscle mass and body composition enhancement, metabolic health, anti-aging, recovery and rehabilitation.

Research Studies

Clinical Trials

Limited human studies have demonstrated promising initial safety and efficacy.

Preclinical Studies

Animal studies consistently report increased lean muscle mass, reduced body fat, and enhanced physical capabilities.

Frequently Asked Questions

Is Ipamorelin legally available? Yes, Ipamorelin is legally available for research purposes from specialized suppliers but is not approved for general therapeutic use. Have human trials been conducted with Ipamorelin? Limited human studies have demonstrated promising initial safety and efficacy; however, extensive research is required to validate these findings fully. What are potential side effects of Ipamorelin? Side effects reported are typically mild and include injection site reactions, headaches, and transient nausea. Due to its selective nature, severe hormonal imbalances are uncommon but warrant ongoing study. How is Ipamorelin typically administered? Ipamorelin is generally administered via subcutaneous injections, typically in research settings, with dosage protocols adjusted based on experimental objectives. Can Ipamorelin be combined with other peptides or treatments? Yes, Ipamorelin is frequently combined in research settings with other GH secretagogues or performance-enhancing agents. However, careful controlled studies are necessary to evaluate interactions and ensure safety. Does Ipamorelin permanently elevate GH levels? Ipamorelin effectively elevates GH levels during administration, but sustained elevations and long-term benefits typically require ongoing use or adjunctive therapies.

Quick Information

Safety Information

Safety Profile

Selective mechanism minimizes side effects; ongoing research required for comprehensive safety guidelines.

Contraindications

Side Effects: Mild side effects include injection site reactions, headaches, and transient nausea. Severe hormonal imbalances are uncommon. Safety Profile: Selective mechanism minimizes side effects; ongoing research required for comprehensive safety guidelines.

Side Effects

Mild side effects include injection site reactions, headaches, and transient nausea. Severe hormonal imbalances are uncommon.

Research References

Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. Bowers, C.Y., et al. (1997). GH releasing peptides—structure and kinetics. Journal of Pediatric Endocrinology and Metabolism. Svensson, J., et al. (2000). Effects of growth hormone secretagogues on body composition and muscle strength in healthy elderly subjects. Journal of Clinical Endocrinology & Metabolism.

Additional Resources